Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma

Abstract

The assessment of caveolin-1 (Cav-1) as a marker of tumor aggressiveness in pancreatic ductal adenocarcinoma (PDAC). In this study, we examined the expression of Cav-1 in 34 human PDAC tissue samples and the associated peritumoral tissues by immunohistochemistry and western blot. Additionally, we correlated Cav-1 expression with other tissue (Ki-67, p53) and serum (CA 19-9) tumor markers. In the tumor-derived tissue, both tumor cells and blood vessels expressed Cav-1. In contrast, in peritumoral tissue, Cav-1 expression was confined mainly to blood vessels and was only occasionally expressed in ductal or parenchymal cells. Western blot analysis confirmed the overexpression of Cav-1 in pancreatic tumors compared with peritumoral tissue. Cav-1 expression in tumor tissues was correlated with both the Ki-67 LI (r = 0.95, P < 0.0001) and p53 expression (chi2 = 9.91, P < 0.005). Overexpression of Cav-1 was associated with tumor size, grade and stage and Cav-1 expression in tumors was correlated with an increased serum level of CA 19-9 (r = 0.795, P < 0.001). Based on the results of this study, the inclusion of Cav-1 in a putative panel of biomarkers predicting pancreatic cancer aggressiveness is warranted.

Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review)

“…Finally, the authors suggested that positive Cav-1 expression is an independent negative predictor of survival (P=0.0358). In a recent study of 34 pancreatic ductal adenocarcinoma (PDAC) tissue samples, Tanase et al (79) confirmed the prognostic role of the expression of Cav-1. Furthermore, the expression of Cav-1 was found to significantly correlate with Ki-67 and p53, as well as serum levels of CA 19-9.…”

“…Therefore, contradictory roles of Cav-1 expression in human cancer cells have been reported. Certain studies insist that Cav-1 is downregulated and serves as a tumor suppressor in breast cancer (71–73), GC (74), hepatic cancer (75) and mucoepidermoid carcinoma (MEC) of the salivary glands (76); while other studies suggest that the expression levels of Cav-1 are upregulated, consistent with advanced tumor stage, high histological type and the metastasis of human cancer cells, including esophagus (77,78), pancreatic (79), renal (80), prostate (81) and colorectal (82) cancer.…”

“…In pancreatic cancer, Cav-1 is frequently expressed in the tumor tissue compared with the little or no staining identified in chronic pancreatitis specimens, normal ductal epithelium (88) and peritumoral tissue (79,93). The prognostic significance of Cav-1 expression in pancreatic carcinoma was initially demonstrated by Suzuoki et al (88).…”

The Association Between Inflammation and Angiogenesis in Human Pancreatic Adenocarcinoma

“…Extensive research have been performed regarding the local/tissue biomarkers: angiogenic factors [e.g. EGF, VEGF, heparanase, cathepsins (31,32)], matrix metalloproteinase 7, fibroblast activation protein (33), caveolin-1 (34,35) are only a few proteins whose increased expression in pancreatic cancer tissue correlates with an unfavorable prognostic.…”

Significance of Caveolin-1 Regulators in Pancreatic Cancer

“…However, in peritumoral tissue caveolin-1 is mainly expressed in blood vessels and only occasionally expressed in ductal or parenchymal cells. Overexpression of caveolin-1 is associated with tumor size, grade, stage, and increased serum levels of CA19-9 (Tanase et al, 2009).…”